Subjects carrying the CYP2C19*2 A allele (AA or GA genotype) had a higher risk of ESCC than GG and patients carrying at least one variant allele had a 3.19-fold increased risk of developing ESCC. This evidence concerns the gene CYP2C19 and esophageal squamous cell carcinoma.